AURORA CANNABIS INC

Aurora Cannabis Inc. announced the completion of a significant expansion of its EU-GMP manufacturing facility in Leuna, Germany, now named Aurora Horizon. This multi-million dollar investment more than doubles the facility's expected annual flower output and enhances its capacity to produce high-quality, compliant medical cannabis for European markets. The expansion integrates Aurora's proven cultivation practices and proprietary genetics, reinforcing the company's commitment to serving patients in its fastest-growing markets and strengthening its European growth strategy.

Aurora Cannabis provided a business update highlighting the expected benefits from the Safari Flower Company acquisition and strong international performance. The company reaffirmed its fiscal year 2027 Q2 guidance for sequential growth in net revenue and adjusted EBITDA. The acquisition of Safari Flower Company, which received EU-GMP certification, is expected to add incremental revenue and EBITDA. Aurora also noted continued strong performance in Germany and Poland, reinforcing its leadership in key European markets, and ongoing expansion in the UK.

Aurora Cannabis Inc. has responded to an unsolicited take-over bid proposal from Curaleaf Holdings, Inc. Curaleaf's proposal offers an implied consideration of US$4.00 per Aurora Share, comprising 0.3463 Curaleaf subordinate voting shares and US$0.75 in cash, with a cap of US$5.00 per share. Aurora's Board of Directors will establish a special committee of independent directors to evaluate the proposal, emphasizing that the bid was not initiated or solicited by the company.

Aurora Cannabis Inc. has responded to an unsolicited take-over bid intention from Curaleaf Holdings, Inc. Curaleaf proposes to acquire all Aurora Shares for an implied consideration of US$4.00 per share, comprising 0.3463 Curaleaf shares and US$0.75 in cash, with a cap of US$5.00 per share. Aurora's Board of Directors will form a special committee of independent directors to review the proposal, emphasizing that no decision has been made and shareholders do not need to take action at this time.

Aurora Cannabis Inc. announced the voting results from its Annual General Meeting held on August 7, 2026. Shareholders approved fixing the number of directors at five and re-elected all five nominated directors, including CEO Miguel Martin. Ernst & Young LLP was re-appointed as the independent auditor, and the non-binding advisory resolution on executive compensation was also approved.

Aurora Cannabis Inc. announced the voting results from its 2026 Annual General Meeting of Shareholders. Shareholders re-elected all nominated directors, including Miguel Martin, Michael Singer, and Norma Beauchamp, with strong support. Additionally, the appointment of Ernst & Young LLP as auditors and the advisory vote on executive compensation ("Say-on-Pay") were approved. The company expressed pleasure with the shareholder support, which demonstrates confidence in its Board and strategy.

Aurora Cannabis reported fiscal Q1 2027 net revenue of $67.6 million, a 9% decrease year-over-year, primarily due to lower Canadian medical and consumer cannabis sales. This was partially offset by a 17% increase in international medical cannabis net revenue to $43.3 million. The company posted a net loss from continuing operations of $4.0 million, an improvement from the prior year's $10.2 million loss, but Adjusted EBITDA decreased to $3.4 million. Aurora also highlighted the EU-GMP certification for its acquired Safari Flower Company, strengthening its international supply capabilities, and reiterated its focus on global medical cannabis markets.

Aurora Cannabis Inc. reported a significant reduction in net loss from continuing operations for the three months ended June 30, 2026, reaching $(4,033) thousand compared to $(10,186) thousand in the prior year. While net revenue saw a decrease to $67,554 thousand, the company completed the acquisition of Safari Flower Company for $24.73 million to expand its EU-GMP certified cultivation capacity. Aurora reiterated its positive outlook for fiscal year 2027, anticipating new records for revenue and adjusted EBITDA by focusing on global medical cannabis.

Aurora Cannabis Inc. announced that Institutional Shareholder Services Inc. (ISS) has recommended shareholders vote FOR all director nominees and resolutions at the upcoming 2026 Annual General Meeting (AGM). The AGM will be held virtually on August 7, 2026, where shareholders will vote on items including director elections, auditor appointment, and executive compensation. Aurora's Board of Directors unanimously supports these resolutions and encourages shareholders to vote by the August 5, 2026 deadline.

Aurora Cannabis Inc. announced that its wholly-owned subsidiary, Safari Flower Company, has received European Union Good Manufacturing Practice (EU-GMP) certification for its Niagara facility in Ontario. This three-year certification validates Safari's commitment to high international standards for quality and compliance. The achievement significantly strengthens Safari's capability to serve regulated medical cannabis markets globally, including Germany, Poland, and the UK, aligning with Aurora's strategy to expand its international footprint.